Robert Roskoski

Blue Ridge Research and Consulting (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

61h-index20.8kcitations201works44.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PI3K/AKT/mTOR signaling in cancer(21), Protein Kinase Regulation and GTPase Signaling(20), Biochemical and Molecular Research(18), Melanoma and MAPK Pathways(16), Chronic Lymphocytic Leukemia Research(14)

Publications201 total

Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update
Pharmacological Research·2026Open Access
Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer
Pharmacological Research·2025· 1 citedOpen Access
Vascular endothelial cells and angiogenesis
Pharmacological Research·2025Open Access
Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs): A 2025 update
Pharmacological Research·2025· 8 citedOpen Access
Corrigendum to “Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update” [Pharmacol. Res. 200 (2024) 107059]
Pharmacological Research·2025· 1 citedOpen Access
Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update
Pharmacological Research·2025· 43 citedOpen Access
Targeted and cytotoxic inhibitors used in the treatment of breast cancer
Pharmacological Research·2024· 35 citedOpen Access
Targeted and cytotoxic inhibitors used in the treatment of lung cancers
Pharmacological Research·2024· 14 citedOpen Access
Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas
Pharmacological Research·2024· 23 citedOpen Access
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
Pharmacological Research·2024· 319 citedOpen Access
Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases
Pharmacological Research·2023· 15 citedOpen Access
Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States
Pharmacological Research·2023· 19 citedOpen Access
Rule of five violations among the FDA-approved small molecule protein kinase inhibitors
Pharmacological Research·2023· 98 citedOpen Access
Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis
Pharmacological Research·2023· 70 citedOpen Access
Futibatinib (Lytgobi) for cholangiocarcinoma
Trends in Pharmacological Sciences·2023· 15 cited
Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update
Pharmacological Research·2022· 287 citedOpen Access
Trends in NIH Funding to Medical Schools in 2011 and 2020
Academic Medicine·2022· 10 cited
Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
Pharmacological Research·2022· 80 citedOpen Access
Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia
Pharmacological Research·2022· 61 cited
Table of Contents
American Journal Of Pathology·2022Open Access
page 1 of 11Next →

Frequent Co-authors

Kent E. Vrana(3), Paul Cook(1), Maynard E. Neville(1), Fabian Hartl(1), Jonathan J. Witt(1), Yimei Xu(1), Alan H. Stokes(1), Izel Tekin(1), Nurgul Carkaci‐Salli(1), Hans J. Rahmsdorf(1), S. H. Pai(1), P. Ponta(1), Peter Herrlich(1), Michal R. Schweiger(1), F. William Studier(1), Abdollah Sadeghi‐Nejad(1), Fritz Lipmann(1), Wieland Gevers(1), Horst Kleinkauf(1), Chin-Tiong Lim(1)